MPR2d
Fabhalta Approved as First Treatment for C3 Glomerulopathy
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
EMPAVELI's Market Success Underscores Growing Demand for Complement Inhibitor Therapies | DelveInsight
DelveInsight's "EMPAVELI Market Size, Forecast, and Market Insight Report" highlights the details around EMPAVELI, a ...
Fierce Pharma9d
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Novartis9d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...
Benzinga.com20d
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
ARO-C3 is designed to reduce hepatocyte production of complement C3 as a potential ... stage studies Effects on proteinuria (too much protein in the urine): The mean reduction in spot UPCR was ...
FierceBiotech20d
Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort
Both are markers of alternative pathway complement activity ... improved with a 41% reduction in spot [urine protein-to-creatinine ratio].” ARO-C3 is one of Arrowhead’s earliest-stage ...
Nature3y
Protease medicines to catalyse change in complement-targeting therapies
which can generate improved or novel molecules to help correct disease-causing imbalances in the complement and coagulation systems (Fig. 1). Proteases cleave or degrade proteins with high ...
Yahoo Finance20d
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans to present additional results at a ...